4-carbamoyl-4-phenylpiperidine | 80139-80-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-carbamoyl-4-phenylpiperidine
• 英文别名: 4-phenyl-piperidine-4-carboxylic acid amide；4-phenylpiperidine-4-carboxamide acid；4-phenyl-4-piperidinecarboxamide；4-phenylpiperidine-4-carboxamide；4-Phenylpiperidin-4-carboxamid
• CAS: 80139-80-6
• 化学式: C₁₂H₁₆N₂O
• mdl: MFCD16040225
• 分子量: 204.272
• InChiKey: JPUKONSIEHCAQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-carbamoyl-4-phenylpiperidine 在 三溴化硼 、 potassium carbonate 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 1-({4-(2,4-Dichlorophenyl)-5-[4-(3-hydroxypropoxy)phenyl]thien-2-yl}carbonyl)-4-phenylpiperidine-4-carboxamide
  参考文献：
  名称：

  THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

  摘要：

  本发明涉及与式（I）相对应的化合物，其中：R1和R2与它们连接的氮原子一起构成一个饱和的杂环基团，含有4到7个原子，最好是取代的；两个取代基R3和R6中的一个是一个Y-A-R9基团；Y是氧原子或-S(O)n′-或-OSO2基团；A是未取代的（C1-C4）烷基基团；R9是-OR19，-CH3，-NR19R20，-CONR19R20，-NR15COR19，-S(O)nR21或-NR13SO2R21基团；-R10是氢原子或（C1-C4）烷基基团。本发明还涉及制备方法和化合物（I）的治疗用途。

  公开号：

  US20110183960A1
• 作为产物：
  描述：

  4-phenyl-piperidine-4-carboxylic acid benzylamide 在 三氟甲磺酸 作用下， 以 甲苯 为溶剂， 反应 0.25h， 以81%的产率得到4-carbamoyl-4-phenylpiperidine
  参考文献：
  名称：

  Microwave-assisted N-debenzylation of amides with triflic acid

  摘要：

  A new and facile microwave-assisted protocol for the debenzylation of N-benzylamides with triflic acid has been developed. Both secondary and tertiary aliphatic or aromatic amides are obtained in moderate to good yields. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.07.022

文献信息

• 2a-[4-(Tetrahydropyridoindol-2-yl)butyl]tetrahydrobenzindole Derivatives:  New Selective Antagonists of the 5-Hydroxytryptamine₇ Receptor
  作者：Chika Kikuchi、Takashi Ando、Takashi Watanabe、Hiroshi Nagaso、Masayo Okuno、Toyokazu Hiranuma、Masao Koyama

  DOI：10.1021/jm0104264

  日期：2002.5.1

  the 5-HT7 receptor, and the 9-carbamoyl moiety afforded increased selectivity. Compound 26j exhibited high affinity for the 5-HT7 receptor, with at least 280-fold selectivity over the 5-HT2 receptor. In a functional model of 5-HT7 receptor activation, this compound was confirmed to have 5-HT7 receptor antagonist activity. It should be a useful tool for clarifying the biological role of the 5-HT7 receptor

  制备了一系列四氢苯并吲哚，并评估了这些化合物对5-羟基色胺7（5-HT7）受体和其他受体的亲和力。大多数化合物对5-HT7受体显示出高亲和力，而2a- [4-（四氢吡啶并吲哚-2-基）丁基]四氢苯并吲哚衍生物（26a-j）对该受体具有高选择性。在四氢吡啶并吲哚环的9位上的取代基的性质影响了对5-HT7受体的亲和力，并且9-氨基甲酰基部分提供了增加的选择性。化合物26j显示出对5-HT7受体的高亲和力，其选择性是5-HT2受体的至少280倍。在5-HT7受体活化的功能模型中，证实该化合物具有5-HT7受体拮抗剂活性。
• Benzimidazole derivatives, preparation and therapeutic use thereof
  申请人：——

  公开号：US20030203893A1

  公开（公告）日：2003-10-30

  The invention relates to benzimidazole derivatives of general formula 1 in which X represents a nitrogen atom or a carbon atom; and when X represents a nitrogen atom: R3 represents a hydrogen atom or a C1-C4 alkyl group, or does not exist, to give the compounds of formula (I) comprising a secondary or tertiary amine; R4 represents a hydrogen atom or a C1-C6 alkyl, C3-C7 cycloalkyl, optionally substituted C3-C7 heterocycloalkyl, —(CH 2 ) p -heteroaryl, heteroaryl-carbonyl, phenylcarbonyl, (C1-C6)alkylcarbonyl, —(CH 2 ) p COOR, optionally substituted phenylsulphonyl or optionally substituted —(CH 2 ) p -phenyl group, and, when X represents a carbon atom: p2 R3 represents a hydrogen atom or a group —NR5R6, —N(R5) 3 + , —NHCOR7, —CONHR5, —COR7, —NHCONH 2 , —OH or —CH 2 OH, R4 represents a hydrogen atom or an optionally substituted —(CH 2 ) p -phenyl, —(CH 2 ) p -heteroaryl or —(CH 2 ) t NR7R8 group. Preparation process and therapeutic application.

  该发明涉及一般式1的苯并咪唑衍生物，其中X代表氮原子或碳原子；当X代表氮原子时：R3代表氢原子或C1-C4烷基基团，或不存在，以给出包含二级或三级胺的式(I)化合物；R4代表氢原子或C1-C6烷基，C3-C7环烷基，可选择取代的C3-C7杂环烷基，—(CH2)p-杂环芳基，杂环芳基-酰基，苯基-酰基，(C1-C6)烷基酰基，—(CH2)pCOOR，可选择取代的苯磺酰基或可选择取代的—(CH2)p-苯基；当X代表碳原子时：R3代表氢原子或基团—NR5R6，—N(R5)3+，—NHCOR7，—CONHR5，—COR7，—NHCONH2，—OH或—CH2OH，R4代表氢原子或可选择取代的—(CH2)p-苯基，—(CH2)p-杂环芳基或—(CH2)tNR7R8基团。制备过程和治疗应用。
• PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
  申请人：Barth Francis

  公开号：US20110152320A1

  公开（公告）日：2011-06-23

  The subject of the invention is compounds of formula (I): in which R 1 -R 10 are as defined within, the method of preparation and therapeutic application as cannabinoid CB1 receptor antagonists.

  本发明的主题是公式（I）的化合物： 其中R1-R10如定义，制备方法和治疗应用作为大麻素CB1受体拮抗剂。
• Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them
  申请人：——

  公开号：US20040220223A1

  公开（公告）日：2004-11-04

  Compounds of formula (I), a method for obtaining them and pharmaceutical compositions containing them are described. The compounds are useful as human NK 3 receptor antagonists.

  本文描述了化学式（I）的化合物，获得它们的方法以及含有它们的药物组合物。这些化合物可用作人类NK3受体拮抗剂。
• Heterocyclo inhibitors of potassium channel function
  申请人：——

  公开号：US20040110793A1

  公开（公告）日：2004-06-10

  Novel heterocyclo compounds useful as inhibitors of potassium channel function (especially inhibitors of the K v 1 subfamily of voltage gated K + channels, especially inhibitors K v 1.5 which has been linked to the ultra-rapidly activating delayed rectifier K + current I Kur ), methods of using such compounds in the prevention and treatment of arrhythmia and I Kur -associated conditions, and pharmaceutical compositions containing such compounds.

  新型杂环化合物可用作钾通道功能抑制剂（特别是Kv1亚家族电压门控K+通道的抑制剂，特别是与超快速激活延迟整流K+电流IKur相关的Kv1.5抑制剂），使用这些化合物在预防和治疗心律失常和IKur相关疾病方面的方法，以及含有这些化合物的药物组合物。